Reviewing Amylyx Pharmaceuticals (NASDAQ:AMLX) and Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions (NYSE:EBS) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Valuation and Earnings

This table compares Emergent Biosolutions and Amylyx Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90 million	0.42	$52.60 million	($5.10)	-1.18
Amylyx Pharmaceuticals	$87.37 million	45.48	-$144.74 million	($1.44)	-21.47

Emergent Biosolutions has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Emergent Biosolutions has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.

Profitability

This table compares Emergent Biosolutions and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-40.16%	-0.43%	-0.15%
Amylyx Pharmaceuticals	N/A	-41.54%	-38.91%

Analyst Ratings

This is a breakdown of recent ratings for Emergent Biosolutions and Amylyx Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2	1	3	0	2.17
Amylyx Pharmaceuticals	1	0	6	2	3.00

Emergent Biosolutions presently has a consensus target price of $10.00, indicating a potential upside of 65.70%. Amylyx Pharmaceuticals has a consensus target price of $43.71, indicating a potential upside of 41.42%. Given Emergent Biosolutions’ higher probable upside, research analysts clearly believe Emergent Biosolutions is more favorable than Amylyx Pharmaceuticals.

Institutional & Insider Ownership

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals beats Emergent Biosolutions on 8 of the 14 factors compared between the two stocks.

About Emergent Biosolutions

Emergent BioSolutions Inc. is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings. The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.